Pretreatment characteristics of the study groups
| . | VSAA group . | G-CSF+ group . | G-CSF− group . |
|---|---|---|---|
| Randomized | 50 | 35 | 34 |
| Evaluable | 46 | 33 | 31 |
| Sex (M/F) | 23/23 | 14/19 | 19/12 |
| Median age, years (range) | 9 (1-18) | 8 (2-16) | 9 (1-15) |
| Cause of aplastic anemia | |||
| Idiopathic | 37 | 26 | 25 |
| Hepatitis | 9 | 6 | 6 |
| Drug | 0 | 1 | 0 |
| Median days from diagnosis to treatment (range) | 12 (1-140) | 38 (3-180) | 26 (3-166) |
| Severity of disease | |||
| Very severe | 46 | 0 | 0 |
| Severe | 0 | 18 | 18 |
| Moderate | 0 | 15 | 13 |
| Median neutrophil count × 109/L (range) | 0.08 (0-0.19) | 0.48 (0.21-1.40) | 0.46 (0.21-1.40) |
| Median platelet count × 109/L (range) | 7 (2-25) | 13 (1-56) | 14 (3-41) |
| Median reticulocyte count × 109/L (range) | 7 (0-41) | 32 (3-75) | 29 (6-117) |
| . | VSAA group . | G-CSF+ group . | G-CSF− group . |
|---|---|---|---|
| Randomized | 50 | 35 | 34 |
| Evaluable | 46 | 33 | 31 |
| Sex (M/F) | 23/23 | 14/19 | 19/12 |
| Median age, years (range) | 9 (1-18) | 8 (2-16) | 9 (1-15) |
| Cause of aplastic anemia | |||
| Idiopathic | 37 | 26 | 25 |
| Hepatitis | 9 | 6 | 6 |
| Drug | 0 | 1 | 0 |
| Median days from diagnosis to treatment (range) | 12 (1-140) | 38 (3-180) | 26 (3-166) |
| Severity of disease | |||
| Very severe | 46 | 0 | 0 |
| Severe | 0 | 18 | 18 |
| Moderate | 0 | 15 | 13 |
| Median neutrophil count × 109/L (range) | 0.08 (0-0.19) | 0.48 (0.21-1.40) | 0.46 (0.21-1.40) |
| Median platelet count × 109/L (range) | 7 (2-25) | 13 (1-56) | 14 (3-41) |
| Median reticulocyte count × 109/L (range) | 7 (0-41) | 32 (3-75) | 29 (6-117) |
VSAA, very severe aplastic anemia.